Mikael Dolsten, Pfizer CSO
May 4, 2022 10:41 AM EDT
Cell/Gene Tx
FDA+

FDA re­leas­es sec­ond Pfiz­er gene ther­a­py from clin­i­cal hold, as he­mo­phil­ia pro­gram gets OK to restart

Lei Lei Wu

News Reporter

The FDA has re­leased a clin­i­cal hold on Pfiz­er and Sang­amo’s he­mo­phil­ia A gene ther­a­py af­ter or­der­ing the com­pa­nies to stop the tri­al last year …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times